Hyogen® Editions

Hyogen® : Superior Enzootic Pneumonia Protection.

Higher efficacy of Hyogen single dose vaccination compared to M.hyo two-shots vaccines 

A randomized field trial was conducted on an Austrian farrow-to-finish farm for one year to compare the efficacy of two commercial Mycoplasma hyopneumoniae vaccines (Cvjetkovic 2018). 585 piglets either received the one-shot formulation in group 1 (Hyogen®, 23.9 days of age) or a two-shot vaccine ( Mycoplasma, 4.3 and 24.0 days of age) in group 2. Assessment of vaccine efficacy was evaluated by regression analyses through cough monitoring from nursery to slaughter, average daily weight gain from inclusion to slaughter, antibiotic treatment rate (ATR), mortality rate and lung lesion assessment at slaughter....

Download the complete study 

HYOGEN® protects pigs against a double Mhyo Challenge 

In an experimental trial performed in the University of Ghent and published during ESPHM congress in 2016, a double M. hyo strain challenge tried to stimulate the situation of multiple infections which can occur in the farm condition.

Vaccination with Hyogen® modified the immune response in a way that the local antibody response in the initial phase post infection was stronger than the positive control and the production of the pro-inflammatory cytokines was milder than the positive control, yet still higher than the negative control. Such “more appropriate” immune response may be a decisive factor of protection with the immune system activated enough to struggle with the germ (lower M. hyo qPCR) yet not too much to stimulate chronic inflammatory processes and development of extensive chronic pneumonia...

Download the complete study

HYOGEN® reduces coughing more than other vaccines 

The results of this field study performed in France showed that Hyogen® provided better protection of pigs than a competitor vaccine, measured by the clinical course of the disease and the lung lesion score. The average number of recorded coughs using microphones in the barn during the whole fattening period was significantly lower in the Hyogen® group. Higher ADG for 44 grams corresponded to the improvements in the respiratory health and was associated with 2.45€ profit in favor of Hyogen® group...

>>>>>>>To Read More please , click to download the complete Study

 Download the complete study

HYOGEN® profitable even in high health farm

This study confirmed that mild M. hyo infections might be underestimated in commercial swine farms with high health status. The results of this study performed in France revealed significant consistent improvements in the incidence and extension of the EP like lesions in Hyogen® vaccinated pigs with highly reduced variability among different batches. As a consequence of the improved respiratory health the growth performance was better in the Hyogen® group, which had on average 34 grams more in the daily weight gain representing a net profit using Respinomics™ application of 1.43€ per pig.

>>>>>>>To Read More please , click to download the complete Study

 Download the complete study

Prevention of enzootic pneumonia with Hyogen compared to PCV2+Mhyo combined vaccine

Hyogen® proved to be a highly efficient M. hyo vaccine, in many well documented trials outperforming other commercially available mono-valent vaccines. Piglets are usually vaccinated around weaning which is the timing and occasion convenient also for the vaccination against PCV2. That is why the ready to-use PCV2 and M. hyo combined vaccines were recently licensed and introduced to the market. However, in some of them the efficacy especially of the M. hyo valence may be compromised. In two large scale field trials performed in Spain, Hyogen® administered as a single dose M. hyo vaccine protected pigs better against the infection and development of specific lesion in the lungs. Higher protection brought almost 2,5€ profit per vaccinated pig.

Download the complete study

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top